NASDAQ, MRNA - Moderna Inc
We are a clinical-stage biopharmaceutical company focusing on the development
and commercialization of innovative therapeutic products based on our
proprietary molecular biology-based nasal drug delivery technology and our
proprietary ribonucleic acid interference (?RNAi?) technology. Using our nasal
drug delivery technology, we create and utilize novel formulation components or
excipients that are designed to reversibly open the ?tight junctions? between
cells in various tissues and thereby deliver therapeutic drugs to the blood
stream. Tight junctions are cell-to-cell connections in various tissues of the
body, including the epithelial layer of the nasal mucosa, the gastrointestinal
tract and the blood-brain barrier, which function to regulate the transport and
passage of molecules across these natural boundaries.
Through our expertise in tight junction biology, we are developing clinical
product candidates in multiple therapeutic areas. ...
Read SEC Filing on NASDAQ.com »